Schumer Questions Whether Trump Is Actually Taking Hydroxychloroquine

Senate Minority Leader Chuck Schumer (D-NY) speaks to the media about his decision not to attend a meeting with President Donald Trump, during a press conference at the US Capitol on November 28, 2017. (SAUL LOEB/AFP/Getty Images)

Senate Minority Leader Chuck Schumer (D-NY) on Tuesday morning cast doubt on President Donald Trump’s claim to be taking hydroxychloroquine, an anti-malaria drug, to ward off COVID-19 infection.

“This president doesn’t tell the truth,” Schumer said during an interview on “Morning Joe.” “He may be taking this, he may not.”

The Democratic leader suggested that Trump may have had an ulterior motive when he told reporters on Monday about supposedly taking the drug, which has not been scientifically proven to prevent COVID-19.

“Maybe he has family or friends who own part of the company. It’s not unlike this president,” Schumer said. “Someone at Mar-A-Lago or someone on the phone tells him ‘oh this is a good company’ and he just talks about it.”

The New York senator had expressed similar skepticism of Trump’s claim the night before.

“Who knows if it’s true?” Schumer said during an interview with MSNBC anchor Steve Kornacki on Monday. “He may not have been taking it, for all we know.”

Indeed, Trump physician Dr. Sean Conley’s memo to White House Press Secretary Kayleigh McEnany on the drug doesn’t definitively state that the President is actually taking it, only that the two of them “concluded the potential benefit from treatment outweighed the relative risks.”

The other half of the memo merely notes that Conley will “continue to monitor the myriad studies investigating potential COVID-19 therapies,” and that he anticipates “employing the same shared medical decision making based on the evidence at hand in the future.”

Schumer slammed Trump’s comment as “reckless” on Tuesday given that not only have studies failed to prove that hydroxychloroquine cures COVID-19, Trump’s own Food and Drug Administration (FDA) has warned of reported “serious heart rhythm problems” associated with the drug.

Read Conley’s letter below:

Dear Reader,

When we asked recently what makes TPM different from other outlets, readers cited factors like honesty, curiosity, transparency, and our vibrant community. They also pointed to our ability to report on important stories and trends long before they are picked up by mainstream outlets; our ability to contextualize information within the arc of history; and our focus on the real-world consequences of the news.

Our unique approach to reporting and presenting the news, however, wouldn’t be possible without our readers’ support. That’s not just marketing speak, it’s true: our work would literally not be possible without readers deciding to become members. Not only does member support account for more than 80% of TPM’s revenue, our members have helped us build an engaged and informed community. Many of our best stories were born from reader tips and valuable member feedback.

We do what other news outlets can’t or won’t do because our members’ support gives us real independence.

If you enjoy reading TPM and value what we do, become a member today.

TPM Staff
Latest News
Masthead Masthead
Founder & Editor-in-Chief:
Executive Editor:
Managing Editor:
Associate Editor:
Investigations Desk:
Director of Audience:
Editor at Large:
General Counsel:
Head of Product:
Director of Technology:
Associate Publisher:
Front End Developer:
Senior Designer: